Combined oxidative phosphorylation defect type 14 is a rare inherited condition that affects how the body’s cells make energy. It is usually recognized in infancy or early childhood, often because the early signs of Combined oxidative phosphorylation defect type 14 include low muscle tone, developmental delay, seizures, or feeding problems. Not everyone will have the same experience. Combined oxidative phosphorylation defect type 14 is lifelong, and severe cases can be life-threatening, especially when the brain, muscles, or breathing are affected. There is no cure, so treatment focuses on supportive care such as seizure control, nutrition support, physical therapy, and close follow-up with specialists.
How many people live with Combined oxidative phosphorylation defect type 14?
No reliable worldwide or U.S. population estimate has been published for combined oxidative phosphorylation defect type 14. For context, the wider group of inherited mitochondrial diseases that affect how cells make energy is often estimated at about 1 in 4,300 people, which works out to roughly 1.9 million people worldwide (Gorman et al., 2015; United Nations, 2024) and about 79,000 people in the United States (Gorman et al., 2015; U.S. Census Bureau, 2024), but type 14 is only one very rare subtype and no direct count, or good percentage to estimate it from, has been reported for this subtype.
Overview
Combined oxidative phosphorylation defect type 14Symptoms
Combined oxidative phosphorylation defect type 14 usually causes severe early-life features affecting the brain and muscles. Many babies have weak muscle tone, feeding problems, developmental delay, seizures, and trouble breathing.
Outlook and prognosis
The outlook for Combined oxidative phosphorylation defect type 14 varies widely. Early-onset disease often brings severe seizures, feeding problems, and a shortened lifespan, while later-onset forms may progress more slowly, with longer survival but ongoing movement, speech, and learning challenges.
Causes and risk factors
Combined oxidative phosphorylation defect type 14 is caused by a gene change, usually inherited from both parents, though a new change can happen. Family history raises risk. Lifestyle does not cause it, but illness and other stresses may affect how severely it shows up.
Genetic influences
Genetics are central to Combined oxidative phosphorylation defect type 14, because it is caused by changes in a gene involved in how cells make energy. Different genetic variations can affect how severe the condition is and which problems appear early.
Diagnosis
Combined oxidative phosphorylation defect type 14 is usually diagnosed by a specialist based on clinical features and supportive lab findings, often followed by genetic tests. In some cases, imaging or other organ checks also help confirm the diagnosis of Combined oxidative phosphorylation defect type 14.
Treatment and drugs
Treatment for combined oxidative phosphorylation defect type 14 focuses on symptoms and supportive care. Many need help with feeding, growth, seizures, and physical therapy for weak muscles or delayed development. Care is usually guided by a metabolic or mitochondrial specialist.
Symptoms
Combined oxidative phosphorylation defect type 14 can make everyday things like feeding, movement, and learning harder because the body has trouble making enough energy for the brain and muscles. The early features of Combined oxidative phosphorylation defect type 14 often include low muscle tone, developmental delay, feeding trouble, or seizures, although some people mainly develop leg stiffness and walking problems. Features vary from person to person and can change over time. Some children have a severe form in infancy, while others have a milder pattern that mainly affects movement and development.
Babies and children may be slower to hold up the head, sit, crawl, walk, or learn to speak. In daily life, this often means needing extra support with movement, communication, and everyday skills.
Seizures can begin in infancy or early childhood and may look like staring spells, body stiffening, or jerking movements. In some children, seizures happen often or are hard to fully control with treatment.
Many living with Combined oxidative phosphorylation defect type 14 have low muscle tone and muscle weakness, so the body may seem floppy or tire easily. This can make feeding, sitting upright, and active play more difficult.
Some people with Combined oxidative phosphorylation defect type 14 develop tight, stiff leg muscles and overactive reflexes. Walking may look awkward or tiring, and falls can become more common.
How people usually first notice Combined oxidative phosphorylation defect type 14?
The first signs of Combined oxidative phosphorylation defect type 14 are usually noticed in infancy or early childhood, when a baby or young child seems unusually floppy because of low muscle tone, has trouble feeding or gaining weight, or is slower than expected to reach milestones like holding up the head, sitting, or walking. Many living with this condition are first brought to medical attention because of seizures, developmental delay, or episodes of unusual sleepiness, weakness, or breathing problems, especially during illness. How Combined oxidative phosphorylation defect type 14 is first noticed can vary, but families and doctors often recognize it when several early problems appear together rather than as one isolated symptom.
Types of Combined oxidative phosphorylation defect type 14
No distinct types of Combined oxidative phosphorylation defect type 14 are widely recognized.
Can I slow down the onset of symptoms?
No—at this time, there is no good evidence that lifestyle changes or medical treatment can meaningfully delay the start of symptoms in combined oxidative phosphorylation defect type 14, a rare inherited condition that affects how the body makes energy. Healthy sleep, good nutrition, staying active as able, and prompt treatment of infections may support overall health, but they have not been shown to prevent the condition or reliably push symptoms back, and research on ways to change onset is still very limited. There are no well-established preventive medicines or screening steps that are known to stop symptoms from starting, but regular follow-up with a specialist can still help families prepare for problems early and support the best possible day-to-day care.
What genetics can tell you about symptoms
For people living with combined oxidative phosphorylation defect type 14, genetics can help explain why symptoms often affect high-energy parts of the body, especially the brain and muscles, and why problems such as developmental delay, seizures, weak muscle tone, feeding trouble, or movement difficulties may appear. Different disease-causing changes in the same gene can influence the pattern, severity, and age when symptoms begin, so some children become ill in early infancy while others have a milder or later-onset course. Even so, genetics cannot predict every detail, because symptoms can still vary quite a bit from one person or family to another.
Causes and risk factors
The causes of Combined oxidative phosphorylation defect type 14 are genetic, and it results from harmful changes in the FARS2 gene. Most people with this condition inherit one changed copy from each parent, so family history can raise the chance of another affected child. Lifestyle, diet, and exercise do not cause Combined oxidative phosphorylation defect type 14. Researchers are still learning how these pieces fit together. Other genes, overall health, and stresses like infections can affect how severe symptoms become.
What are the most common causes or risk factors?
Combined oxidative phosphorylation defect type 14 is usually caused by harmful changes in a gene called FARS2, which helps the body’s cells make energy. The main risk factors are having a family history of the condition or having two parents who each carry one changed copy of this gene, and this chance can be higher when the parents are blood relatives. It is not thought to be caused by lifestyle, diet, or anything a parent did during pregnancy.
Environmental and biological risk factors
Combined oxidative phosphorylation defect type 14 is a rare condition in which well-established environmental or non-genetic biological risk factors have not been confirmed. Awareness of both biological and environmental influences helps you feel prepared. In practice, this means common pregnancy exposures, parental age, and birth events are not known to be the main reasons it occurs.
Unlike some congenital conditions, exposures such as air pollution, radiation, or common infections have not been clearly linked to Combined oxidative phosphorylation defect type 14. Research is limited because the condition is very rare.
Advanced maternal or paternal age is not a known risk factor for this condition. That pattern is more typical of some chromosome conditions than of Combined oxidative phosphorylation defect type 14.
Mother’s health conditions during pregnancy have not been shown to specifically raise the chance of this condition. Good prenatal care still matters for overall pregnancy health, but it is not known to prevent this disorder.
Prematurity, low oxygen at birth, or delivery complications do not appear to cause this condition. These events can affect a newborn’s health, but they are not established risk factors for Combined oxidative phosphorylation defect type 14.
Genetic risk factors
Problems with the body’s energy supply can affect the brain, muscles, and development very early in life, so families often want clear answers about why this happens. For many families trying to understand the genetic causes of Combined oxidative phosphorylation defect type 14, the key point is that it is usually linked to changes in a gene called FARS2. This gene helps mitochondria, the parts of cells that make energy, build proteins they need to work properly. Carrying a genetic change doesn’t guarantee the condition will appear, because people with one changed copy are usually healthy carriers.
FARS2 changes: Combined oxidative phosphorylation defect type 14 is caused by harmful changes in the FARS2 gene. When this gene does not work properly, mitochondria may struggle to make enough of the proteins needed for normal energy production.
Recessive inheritance: This condition follows an inheritance pattern known medically as autosomal recessive. That means a child usually needs to inherit two altered copies of FARS2, one from each parent, to develop the condition.
Carrier parents: Parents who each carry one altered FARS2 copy are often healthy and may not know they carry it. With each pregnancy, they have a 1 in 4, or 25%, chance of having an affected child.
Family history: A family history of this condition or of similar unexplained problems in siblings can raise the chance that the same gene change is present in the family. Genetic testing may help show whether relatives carry the altered gene.
Related parents: Parents who are biologically related are more likely to carry the same rare gene change. This can increase the chance of recessive conditions, including Combined oxidative phosphorylation defect type 14.
Lifestyle risk factors
Combined oxidative phosphorylation defect type 14 is an inherited mitochondrial condition, so lifestyle habits do not cause it. Still, how lifestyle affects Combined oxidative phosphorylation defect type 14 can matter because daily habits may influence energy balance, symptom burden, and the risk of metabolic worsening. The most helpful approach is usually to support steady energy supply, avoid physical overstrain, and reduce added stress on muscles and the nervous system.
Skipping meals or long fasting periods can make it harder for the body to meet energy needs in this condition. Regular meals and snacks may help reduce fatigue, weakness, or metabolic stress.
Poor overall intake can worsen low energy, muscle problems, and difficulty recovering from illness or exertion. A clinician-guided eating plan that provides enough calories, protein, and key nutrients may better support daily function.
Very intense or prolonged exercise can overwhelm impaired energy production and trigger marked fatigue, muscle symptoms, or delayed recovery. Gentle, paced activity may help maintain mobility and conditioning without pushing the body past its limits.
Inadequate sleep can increase daytime exhaustion and make neurologic or muscle symptoms harder to manage. Consistent sleep and planned rest breaks may help conserve energy in people with mitochondrial disease.
Risk prevention
Because Combined oxidative phosphorylation defect type 14 is a rare inherited condition, there is usually no way to prevent the disorder itself once the gene change is present. Prevention mostly means lowering the chance of complications, avoiding physical stress that can trigger worsening, and supporting growth, breathing, and brain health as closely as possible. For families with a known risk, genetic counseling and genetic testing for Combined oxidative phosphorylation defect type 14 may help with planning. Different people need different prevention strategies—there’s no single formula.
If Combined oxidative phosphorylation defect type 14 runs in a family, meeting with a genetics specialist can help clarify recurrence risk. This may guide family planning, carrier testing, or discussion of testing during a future pregnancy.
Infections can put extra strain on the body and may trigger setbacks in children with Combined oxidative phosphorylation defect type 14. Keeping up with recommended vaccines, handwashing, and early treatment for fever or breathing symptoms can help lower that risk.
Regular feeding, good hydration, and avoiding long gaps without food may help prevent metabolic stress. For babies or children who struggle to feed, a dietitian or specialist team can help support safe nutrition and growth.
Some medicines can stress mitochondria or make symptoms worse in certain mitochondrial disorders. People living with Combined oxidative phosphorylation defect type 14 should have new medicines reviewed by their specialist team whenever possible.
Can you prevent Combined oxidative phosphorylation defect type 14?
No, combined oxidative phosphorylation defect type 14 cannot usually be prevented, because it is a rare condition caused by changes in genes that are present from birth. If this condition runs in your family, meeting with a genetics specialist before pregnancy may help you understand the chances of it happening again and discuss family planning options, but it cannot guarantee prevention.
Transmission
Combined oxidative phosphorylation defect type 14 is not infectious, so it cannot spread from one person to another through close contact, coughing, blood, food, or sex. It is a genetic condition present from birth, and the genetic transmission of Combined oxidative phosphorylation defect type 14 usually happens when a child inherits one changed copy of the related gene from each parent.
In many families, both parents are healthy carriers and may not know they carry the change until a child is affected. This pattern is known medically as autosomal recessive inheritance, and it means each pregnancy has a chance of being affected, while some families may have no previous history of the condition.
When to test your genes
Because combined oxidative phosphorylation defect type 14 is a genetic condition, gene testing is usually considered when a baby or child has unexplained developmental delay, low muscle tone, seizures, feeding problems, or signs of lactic acidosis. Testing can help confirm the diagnosis, guide supportive care, and clarify recurrence risk for your family.
Diagnosis
Combined oxidative phosphorylation defect type 14 is usually suspected when a baby or child has a pattern of serious health problems that do not seem to fit a more common condition. Doctors often look at symptoms such as poor growth, low muscle tone, developmental delay, feeding trouble, seizures, or signs that the brain, liver, or muscles are not working as expected. Because this is a rare inherited condition, the diagnosis of Combined oxidative phosphorylation defect type 14 usually combines clinical findings with lab and genetic testing. Getting a diagnosis is often a turning point toward answers and support.
Doctors begin by looking at the overall pattern of symptoms and exam findings. They consider when problems started, how development is progressing, and whether more than one body system is affected.
A detailed family and health history can help show whether similar illness, early infant deaths, or unexplained neurologic problems have occurred in relatives. This can raise concern for an inherited mitochondrial condition.
Blood and urine tests may show signs that the body is not making energy normally, such as high lactate or other abnormal metabolic results. These tests do not confirm the condition on their own, but they can strongly support the diagnosis of Combined oxidative phosphorylation defect type 14.
Your provider may suggest brain MRI to look for patterns of injury or delayed development in the brain. Imaging findings can help explain symptoms like seizures, weakness, or developmental delay and may point toward a mitochondrial disorder.
How is Combined oxidative phosphorylation defect type 14 diagnosed?
Doctors usually suspect combined oxidative phosphorylation defect type 14 from a child’s symptoms and from tests that show the body’s cells are not making energy normally, such as blood tests that may show high lactic acid, brain scans, and sometimes muscle testing or a small muscle sample called a biopsy. Because its signs can look like other mitochondrial disorders, genetic testing is often used to look for a change in the FARS2 gene and help confirm the diagnosis.
Stages of Combined oxidative phosphorylation defect type 14
Combined oxidative phosphorylation defect type 14 does not have defined progression stages. This is because it is a rare genetic condition that can affect people in very different ways, rather than moving through a clear set of steps over time. Doctors usually start with a conversation about the early symptoms of Combined oxidative phosphorylation defect type 14, along with an exam and tests that may look at brain function, muscle tone, growth, and blood markers linked to energy production. Diagnosis is usually confirmed with genetic testing, and follow-up focuses on watching symptoms, development, and organ function over time.
Outlook and prognosis
The outlook for combined oxidative phosphorylation defect type 14 is highly variable but is often serious, especially when symptoms begin in infancy. Babies with the severe early-onset form can develop refractory seizures, profound developmental impairment, feeding and breathing difficulties, and many die in infancy or early childhood. People with later-onset disease may survive longer, sometimes into adolescence or adulthood, but they often have persistent neurologic problems such as developmental delay, spasticity, movement abnormalities, or epilepsy. Prognosis tends to be worse when there is rapidly progressive brain involvement, severe lactic acidosis, or major organ complications. Treatment is supportive rather than curative, so outcome depends largely on the specific genetic change, age at onset, and the severity of neurologic and metabolic disease.
Long-term effects
For people living with combined oxidative phosphorylation defect type 14, the long-term picture depends a lot on when it starts and which body systems are most affected. Some children have a severe early course, while others live longer with more stable movement and learning difficulties. Long-term effects vary widely, but the brain, muscles, growth, and sometimes breathing can be affected most.
Delays in sitting, walking, speech, and learning are common long-term effects of combined oxidative phosphorylation defect type 14. Many living with combined oxidative phosphorylation defect type 14 continue to need support with communication, school, and day-to-day tasks.
Recurrent seizures can become a major long-term problem, especially in early-onset forms of combined oxidative phosphorylation defect type 14. In some children, seizures are hard to fully control and can add to developmental slowing over time.
Low muscle tone, weakness, stiffness, or spasticity can affect posture, walking, and hand use. For many, this can mean delayed motor milestones, trouble with balance, or loss of skills after illness or other stress on the body.
Some children have ongoing feeding difficulties, poor weight gain, or slow growth because eating takes a lot of effort and energy. In more severe cases, swallowing can become unsafe and nutrition may remain a long-term concern.
How is it to live with Combined oxidative phosphorylation defect type 14?
Living with combined oxidative phosphorylation defect type 14 often means living with a condition that affects how the body makes energy, so daily life can be shaped by low muscle tone, developmental delay, feeding difficulties, seizures, and sometimes problems with movement or breathing. For many families, this can mean frequent medical appointments, therapy visits, careful monitoring during illness, and extra help with feeding, mobility, communication, or daily routines, although the exact challenges can vary from one child to another. The condition also reaches beyond the individual: parents, siblings, and other caregivers often take on intensive hands-on care and emotional strain, while building new routines around safety, treatment, and support.
Treatment and drugs
Combined oxidative phosphorylation defect type 14 is usually treated with supportive care, because there is no single cure that fixes the underlying energy problem in the body’s cells. Treatment often focuses on the symptoms a child or adult is having, such as medicines to help control seizures, physical and occupational therapy for movement or muscle weakness, and nutrition support if feeding is difficult. Treatment plans often combine several approaches, and many living with Combined oxidative phosphorylation defect type 14 are cared for by a team that may include a neurologist, metabolic specialist, therapists, and a dietitian. Because symptoms and severity can vary, the best treatment for Combined oxidative phosphorylation defect type 14 depends on the individual, and regular follow-up helps doctors adjust care as needs change.
Can you cure Combined oxidative phosphorylation defect type 14?
No, there is currently no cure for combined oxidative phosphorylation defect type 14. Treatment focuses on helping with the problems it causes, such as seizures, feeding difficulties, weak muscles, breathing problems, or delays in development, and care is tailored to each person’s needs. While treatment cannot fix the underlying condition, it can sometimes ease symptoms, support day-to-day function, and help prevent complications.
Non-drug treatment
Daily care for Combined oxidative phosphorylation defect type 14 usually centers on helping with movement, feeding, communication, breathing, and learning, since treatment is mainly supportive rather than curative. Managing this condition often means working with several specialists and adjusting support as symptoms change over time. Because this is a rare mitochondrial condition, the mix of therapies can look different from one person to another.
Physical therapy can help with muscle weakness, balance problems, tight muscles, and delayed motor skills. For many living with Combined oxidative phosphorylation defect type 14, this may make transfers, sitting, standing, or walking safer and a little easier.
Occupational therapy focuses on daily activities such as dressing, feeding, play, school tasks, and hand use. It can also help with seating, splints, and other equipment that supports comfort and independence.
Speech and language therapy can support communication, especially when speech is delayed or hard to understand. If swallowing is affected, the same team may help assess safer ways to eat and drink.
Many people with Combined oxidative phosphorylation defect type 14 need careful nutrition support because poor feeding, slow growth, or fatigue with eating can become major day-to-day issues. Some may do well with texture changes, high-calorie meals, or tube feeding when eating by mouth is no longer enough.
Your genes may have an impact on how drugs work for you
For people living with combined oxidative phosphorylation defect type 14, the same genetic change that affects how the body makes energy can also change how well some medicines are tolerated, especially if a drug puts extra stress on muscles, the liver, or the nervous system. This can mean that a treatment helping one person may cause more side effects or work less well in another, so doctors often choose medicines carefully and watch closely for problems like worsening weakness, sleepiness, or stomach upset. In this condition, day-to-day care usually matters more than specialized drug-gene testing, but a person’s exact genetic diagnosis can still help guide safer treatment choices.
Pharmacological treatments
For Combined oxidative phosphorylation defect type 14, treatment is usually aimed at easing symptoms because there is no proven medicine that corrects the underlying energy problem in the cells. Medication can feel like a big step, but care often focuses on problems such as seizures, muscle stiffness, feeding issues, or low carnitine if testing shows it. Because this condition is rare, doctors usually tailor medicines to the symptoms each person has and how severe they are.
Antiseizure drugs such as levetiracetam, clobazam, and topiramate may be used when Combined oxidative phosphorylation defect type 14 causes epilepsy. The best choice depends on the seizure type, age, and side effects, and early symptoms of Combined oxidative phosphorylation defect type 14 can sometimes include hard-to-control seizures. Some doctors avoid or use extra caution with valproic acid in mitochondrial disease because it can worsen liver problems in some people.
Coenzyme Q10, riboflavin, thiamine, and biotin are sometimes prescribed as part of a mitochondrial supplement plan. These medicines and supplements are used in hopes of supporting cell energy production, but strong proof of benefit in Combined oxidative phosphorylation defect type 14 is limited. Not everyone responds to the same medication in the same way.
Levocarnitine may be given if blood tests show low carnitine levels or if a specialist thinks it may help energy metabolism. It is not a cure, and it is usually used selectively rather than automatically for everyone with Combined oxidative phosphorylation defect type 14.
Baclofen is often used if muscle tightness or spasticity makes movement, positioning, or daily care harder. In some people, this can ease discomfort and make stretching or physical therapy easier.
Genetic influences
For families facing combined oxidative phosphorylation defect type 14, genetics are central rather than just one possible risk factor. This specific type is caused by harmful changes in both copies of the FARS2 gene, which helps the mitochondria — the energy-making parts of cells — produce proteins they need to work properly. A “carrier” means you hold the gene change but may not show symptoms. In most families, each parent carries one changed copy, and a child develops combined oxidative phosphorylation defect type 14 only after inheriting both changed copies, which is called autosomal recessive inheritance. Different FARS2 changes can affect energy production in different ways, so the condition may not look exactly the same in everyone, and genetic testing for combined oxidative phosphorylation defect type 14 can help confirm the diagnosis and clarify risks for other family members.
Is Combined oxidative phosphorylation defect type 14 genetic?
Genetics are central to Combined oxidative phosphorylation defect type 14, because it is caused by changes in a gene involved in how cells make energy. Different genetic variations can affect how severe the condition is and which problems appear early.
Having a genetic risk is not necessarily a diagnosis
It is normal for people to have genetic variants, and these are common across the population. Most of them do not directly affect health and are simply part of natural human diversity. For many genes, having a variant tied to a condition means there may be an association, not that the condition is definitely present, especially when several genes and environmental factors contribute. Still, in certain cases, one well-studied variant in a particular gene can on its own confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
For families dealing with seizures, low muscle tone, or feeding problems, treatment for Combined oxidative phosphorylation defect type 14 is usually based on the symptoms someone is having, not on a single medicine that corrects the underlying genetic change. This condition is linked to changes in a gene involved in how mitochondria make energy, so genetic testing mainly helps confirm the diagnosis and explain why the illness affects several body systems at once. Beyond trial and error, genetics offers another way to guide care by helping doctors choose monitoring, supportive therapies, and specialist follow-up that fit the pattern of disease. At this point, there is no routine gene-specific drug that reliably treats Combined oxidative phosphorylation defect type 14 itself, so care often includes seizure treatment, nutrition support, and physical, occupational, or breathing support as needed. Many living with Combined oxidative phosphorylation defect type 14 may respond differently to medicines, so doctors usually prescribe carefully and watch closely for side effects, especially with drugs that could add stress to already fragile energy-making cells. Genetic results can also help families understand recurrence risk and, in some cases, make it easier to join research studies or future treatment trials.
Interactions with other conditions
For families living with Combined oxidative phosphorylation defect type 14, everyday health problems such as viral infections, stomach bugs, or poor feeding can put extra stress on the body and make symptoms worse. Because this condition affects how cells make energy, other illnesses may bring on more weakness, low muscle tone, seizures, breathing problems, or developmental setbacks, and the early symptoms of Combined oxidative phosphorylation defect type 14 can become more noticeable during these times. Doctors call it a “comorbidity” when two conditions occur together. Many people with Combined oxidative phosphorylation defect type 14 may also have problems involving the brain, liver, heart, or hearing, and these can complicate care if another disease affects the same organs. Some may also be more sensitive to dehydration, long gaps without food, or medicines that strain the liver or mitochondria, so treatment for unrelated illnesses often needs extra care. Because Combined oxidative phosphorylation defect type 14 is rare and can overlap with other metabolic or neurologic disorders, coordinated care helps clinicians sort out whether new symptoms are part of the condition itself or triggered by another illness.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Combined oxidative phosphorylation defect type 14?
Other mitochondrial diseases, especially Leigh syndrome and other rare conditions that stop cells from making energy properly, can look very similar to combined oxidative phosphorylation defect type 14. Doctors may also consider other inherited body-chemistry disorders present from birth, as well as some seizure, muscle, or brain conditions that can cause developmental delay, weak muscle tone, trouble with movement, or a buildup of lactic acid in the blood.
History
For many families, the story starts long before there is a name for what is happening. A baby may have trouble feeding, seem unusually floppy, or begin having seizures early in life, while another child in the same family may develop more slowly and show symptoms later. These patterns helped doctors recognize that some illnesses affecting the body’s energy supply could run in families, even when the exact cause was still unclear.
At first, conditions like combined oxidative phosphorylation defect type 14 were understood mainly through their symptoms. Doctors could see that affected children often had problems in organs that need a lot of energy, especially the brain and muscles, but earlier medicine could not easily explain why. As testing improved in the late 20th century, researchers began linking these illnesses to the mitochondria, the parts of cells that help turn food into usable energy.
In recent decades, awareness has grown, and that changed the picture for many living with rare mitochondrial conditions. Instead of grouping people together only by shared symptoms, specialists began separating these disorders into smaller, more precise types based on the underlying genetic change. This led to the recognition of combined oxidative phosphorylation defect type 14 as one of several inherited conditions that disrupt the cell’s energy-making system.
The next major step came with genetic testing. Researchers identified changes in a gene called FARS2 in people with this condition, helping explain why symptoms can look similar in some families but quite different in others. That discovery also made it easier to confirm the diagnosis in children with early symptoms of combined oxidative phosphorylation defect type 14, especially when standard exams suggested a mitochondrial disease but did not show the exact subtype.
The history of this condition is still fairly recent compared with better-known disorders. Even so, each new diagnosed case has added to what doctors understand about the range of symptoms, how the condition may change over time, and why severity can vary from one person to another. Today, the condition is recognized as a rare genetic mitochondrial disorder, and its history continues to grow as more families receive answers through modern genetic testing.